GILD analyst estimates
Gilead (GILD) analyst ratings, the average price target and its range, and every firm's latest call.
GILD analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 30, 2026 | BMO Capital | Gilead Sciences (GILD) PT Raised to $184 at BMO Capital | $184.00 |
| Oct 30, 2026 | Needham | Gilead Sciences (GILD) PT Raised to $175 at TD Cowen | $175.00 |
| Oct 30, 2026 | UBS | Gilead Sciences (GILD) PT Raised to $195 at UBS on Revenue Beat, Raised Guidance | $195.00 |
| Oct 23, 2026 | Jefferies | Gilead Sciences (GILD) PT Raised to $185 at Jefferies | $185.00 |
| Oct 12, 2026 | Raymond James | Gilead Sciences (GILD) PT Raised to $164 at BofA Securities | $164.00 |
| Oct 8, 2026 | RBC Capital | Gilead price target raised to $126 from $123 at RBC Capital | $126.00 |
| Oct 7, 2026 | Truist Financial | Gilead price target raised to $158 from $150 at Truist | $158.00 |
| Sep 10, 2026 | HSBC | Gilead price target raised to $175 from $155 at HSBC | $175.00 |
| Aug 5, 2026 | RBC Capital | Gilead price target raised to $123 from $120 at RBC Capital | $123.00 |
| Aug 5, 2026 | Truist Financial | Gilead price target lowered to $150 from $156 at Truist | $150.00 |
| Jul 29, 2026 | Barclays | Gilead price target lowered to $145 from $155 at Barclays | $145.00 |
| Jul 27, 2026 | Morgan Stanley | Gilead price target lowered to $165 from $166 at Morgan Stanley | $165.00 |
| Jul 20, 2026 | Leerink Partners | Gilead downgraded to Market Perform from Outperform at Leerink | $127.00 |
| Jul 8, 2026 | Morgan Stanley | Gilead price target lowered to $166 from $168 at Morgan Stanley | $166.00 |
| Jul 7, 2026 | RBC Capital | Gilead price target lowered to $120 from $122 at RBC Capital | $120.00 |
- 17 firms rate GILD: 14 buy, 3 hold, 0 sell.
- The average price target is $163.55 from 11 analysts, from $126.00 to $195.00.
Updated 2026-11-02 17:56 UTC